Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regulus Therapeutics 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 USA

www.regulusrx.com Employees: 34 P: 858-202-6300

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.

Key Statistics

Overview:

Market Capitalization, $K 564,949
Enterprise Value, $K 526,369
Shares Outstanding, K 69,234
Annual Sales, $ 0 K
Annual Net Income, $ -46,360 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -9,630 K
EBIT, $ -51,750 K
EBITDA, $ -52,960 K
60-Month Beta 0.35
% of Insider Shareholders 4.35%
% of Institutional Shareholders 92.38%
Float, K 66,222
% Float 95.65%
Short Volume Ratio 0.09

Growth:

1-Year Return 298.05%
3-Year Return 294.20%
5-Year Return 17.82%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 92.41%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 05/08/25
Next Earnings Date 08/14/25
Earnings Per Share ttm -0.73
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 48.28%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/29/22

RGLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.53%
Return-on-Assets % -53.26%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 7.83
Book Value/Share 1.04
Interest Coverage -288.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar